Innovations That Are Shaping Longevity

🧠 AI Agent-Powered Innovation in Precision Longevity: Redefining How We Age, Adapt, and Thrive 🧬 The future of longevity is no longer about generic supplements or annual checkups—it’s about dynamic orchestration of biology, behavior, and environment through intelligent systems. 🔎 Multi-Omics & Healthspan Platforms LifeNome Inc.: AI-driven personalized wellness protocols based on genomics. GainMed: Longevity intelligence using omics + AI for protocol optimization. InsideTracker: Blood biomarker tracking to optimize healthspan. Viome: Microbiome and gene expression analysis for nutrition & longevity. 🧪 Biological Aging Diagnostics Tally Health: DNA methylation-based biological age testing and recommendations. Elysium Healthcare: Offers the Index biological age test and NAD+ boosters. MyDNAge (Epimorphy LLC): Epigenetic clock testing via saliva and blood. AgeRate: Epigenetic aging analysis to support individualized wellness plans. Grimage Productions and DeepMage: Academic aging clocks powering several commercial platforms. ⌚ Wearables & Digital Phenotyping WHOOP 4.0: Strain, recovery, HRV for performance-driven behavior change. BIOSTRAP: Biometric wearables for remote health monitoring and optimization. 🏥 Hybrid Clinical Longevity Programs Human Longevity, Inc.: Whole-genome + imaging + microbiome for deep phenotyping. Fountain Life: Concierge care combining AI diagnostics and regenerative medicine. MaxWell Clinic: Integrative longevity and inflammation-targeted medicine. Sereno Health and Biograph: Advanced diagnostics and cognitive wellness programs. 🧬 Gerotherapeutics & Regenerative Tech Turn Biotechnologies: Epigenetic reprogramming therapies. Rejuvenate Bio: Gene therapies for extending lifespan in animals and potentially humans. Retro Biosciences: Focused on cellular reprogramming and tissue regeneration. Elysium Healthcare, NOVOS, DoNotAge.org, JUVICELL: Supplement providers targeting hallmarks of aging with NAD+, spermidine, urolithin A, etc. 🤖 AI Longevity Coaches & Digital Interfaces Hearty: GPT-powered longevity assistant for lab interpretation and daily guidance. Thorne HealthTech: AI-enabled supplement and health tracking recommendations. Viome: Combines microbiome data with AI to create custom protocols. ⚙️ AI Agent Framework In contrast to static recommendations, the AI Agent-Powered Framework for Precision Longevity introduces an intelligent multi-agent system with modular agents including: Perception Agents – Sensing omics, wearables, behaviors. Pattern Discovery Agents – Detecting phenotypic aging subtypes. Personalization Agents – Designing tailored protocols. Feedback Loop Agents – Real-time adaptation. Explainability Agents – Providing rationale and emotional trust. Federated Learning Agents – Privacy-preserving collective intelligence. #Longevity #AIAgents #Healthspan #PersonalizedHealth #PrecisionMedicine #DigitalHealth #MultiOmic

A new tool can measure biological age and diagnose diseases using just your face’s heat map analysis! A recent study published in Cell Metabolism (link in the comments) introduced ThermoFace, an innovative technology that uses thermal facial imaging to assess biological age and detect early signs of metabolic diseases like diabetes, hypertension, and fatty liver. Key Takeaways: ✔ ThermoFace analyzes temperature patterns on the face, revealing biological age with remarkable accuracy. ✔ Specific temperature changes around the eyes, cheeks, and nose link to chronic conditions, providing early detection of diseases. ✔ Simple interventions, like daily exercise, decrease thermal age, showing the tool’s potential for tracking lifestyle impacts on health. ✔ The technology predicts metabolic disorders with an accuracy exceeding 80%, offering a non-invasive diagnostic alternative. Why Does It Matters? ThermoFace could revolutionize practical healthcare by enabling early diagnosis and personalized health interventions, reducing the burden of age-related diseases. Its non-invasive, quick, and cost-effective nature makes it a promising tool for widespread use. While ThermoFace shows great promise, authors stress that it needs further validation across different ethnic groups and real-world clinical settings to ensure broad applicability. Additionally, environmental and emotional factors may influence facial temperature, which warrants careful consideration during analysis. But let’s face it, this research has some amazing potential! #aging #diagnostics #science Image source: Yu et al., 2024, Cell Metabolism 36, 1482–1493

An important longevity development is too-little discussed in the field for years: Despite many Aβ trial failures (& little benefit of the few successes), there's another misfolded protein possibly as important in aging with much success: ATTR now has 5 FDA approved therapies! TTR is an important protein but ATTR (transthyretin amyloidosis) is a pathological misfolded aggregate involved in many age-related conditions, notably cardiomyopathy (ATTR-CM), but also neuropathies & other age-related conditions (see pic). Importantly, it's widely quoted in scientific literature that ATTR is the primary cause of death of 70% of supercentenarians (age 110+). https://lnkd.in/gunmECuX Most of the rest die of aspiration pneumonia. So effective ATTR tx should extend human lifespans, maybe past 120. There's growing evidence ATTR is involved in cardiac deaths at lower ages too. It's found in 25% of 85+yos on autopsy & ~15% of those considered for valve replacement on scan. https://lnkd.in/g9dq62uA It's widely speculated its underdiagnosed. So tx could lower cardiac deaths generally. What therapies? (all now listed at AgingBiotech.info / therapeutics) patisiran (approved 2018) inotersen ('18) tafamidis ('19) vutisiran ('22) acoramidis (just approved Nov'24) (& a 6th is in phase 3) From 4 different companies. 2 TTR stabilizer drugs. The rest suppress TTR production (by RNAi or ASO). Due to the underdiagnosis, we don't know how much disease burden of the many age-related conditions pic'ed above (eg muscle weakness) is due to ATTR. Non-invasive scans can dx, but expensive. Amprion's seed amplification tech could make a widespread screening blood test w/ a bit of investment $. Important to note that all approved tx so far are not rejuvenative: They slow progression by slowing TTR production or TTR misfolding but don't remove already accumulated ATTR. But Attralus is in phase 2 w/ a removal tx (also w/ a dx). We will need removal eventually so good luck to them! So: Proteostasis is a aging hallmark, SENS area, & pillar. This is a key misfolding protein. It controls mortality of the oldest humans. We have phase-3-clinical-trial-proven FDA-approved therapies & potential diagnostics. We could already be on the way to 120+yo humans. Why is this not talked about more? Let's contrast this topic vs 2 of the most talked about topics in aging/longevity field, GLP-1 drugs & Bryan Johnson: GLP-1 drugs slow aging in overweight/obesity (really they rescue the sped up aging). Bryan's extreme lifestyle optimization tries to optimize longevity w/ everything available. Few in the aging field think Bryan's routine extends his max lifespan much. It improves healthspan so may let him live to see new breakthrus. Few thinks GLP1 drugs help humans exceed 120. ATTR therapies may help everyone 70/80/90yo+ *and* look likely to extend maximum human lifespan.

Aging and disease accelerate when lysosomes fail, and slow down when we fix them. This is an underappreciated, shared mechanism contributing to everything from cellular senescence and #inflammaging to mitochondrial dysfunction and Parkinson's disease. Every cell generates waste—damaged proteins, oxidized lipids, and mitochondria that have exceeded their useful lifespan. Lysosomes recycle this cellular debris, while also coordinating key signaling events that tell cells which nutrients are available and which ones are scarce. But over time, this system breaks down. Lysosomes become swollen, sluggish, and leaky. They stop degrading waste efficiently. Damaged materials pile up—especially in senescent cells, where dysfunctional lysosomes accumulate in bulk. Instead of recycling cellular waste, they start to trigger inflammation and fuel the #aging process. It’s not just passive decline. Lysosomal failure actively drives aging hallmarks like the accumulation of misfolded proteins, mitochondrial dysfunction, senescence and the SASP, chronic inflammation, and deregulated nutrient sensing. Thankfully, lysosomal dysfunction is also highly druggable. In fact, many of the most promising longevity interventions already converge on the lysosome, often by enhancing what’s been called the "lysosomal processing and adaptation system," or LYPAS: • Rapamycin inhibits mTORC1 at the lysosomal surface, releasing the brake on autophagy and activating TFEB—the transcription factor that builds new lysosomes. • Metformin, once thought to target mitochondrial complex I, actually binds to PEN2, a lysosomal membrane protein, and activates AMPK (which is also anchored at the lysosome). • Acarbose and SGLT2 inhibitors mimic caloric restriction, indirectly reducing mTORC1 activity and restoring lysosomal flux. • Compounds like spermidine, trehalose, and lithium each enhance autophagy by stimulating lysosomal turnover or TFEB signaling. • Even 17α-estradiol, in male mice, downregulates growth signaling pathways that suppress lysosomal renewal. These compounds work in part by replacing old, dysfunctional lysosomes with new, functional ones. But many of the best compounds for boosting lysosomal health haven't even been tested for #longevity and #healthspan indications. As this connection gathers more attention, I suspect we'll see breakthroughs here—targeted therapies that preserve lysosomal function throughout the lifespan, preventing decline and disrupting the cascade of aging-related damage. A recent review from Tan & Finkel provides an excellent summary. Link in the comments.

What if your brain and immune system are the real keys to longevity? 🔥 Just out in Nature Medicine 🔥 “Plasma proteomics links brain and immune system aging with healthspan and longevity” by Hamilton Se-Hwee Oh, Tony Wyss-Coray, Anne Brunet, Michael Greicius & colleagues We often talk about aging as a slow, systemic decline ; but what if the real story is about a few crucial organs pulling the strings? We've been studying how immune system aging drives systemic decline for almost 2 decades and reading this elegant paper reaffirms this claim. In this massive study of ~45,000 people from the UK Biobank, Tony's group built machine learning models that estimate the biological age of 11 organs from plasma proteins. 🧬 Key insights: ✅ Each organ ages independently —> brain and immune system stand out ✅ Aged brains increase Alzheimer’s risk as much as carrying an APOE4 allele ✅ Aged immune systems drive mortality and chronic diseases ✅ Youthful brains and immune systems reduce mortality risk by nearly 60% ✅ Individuals with both youthful organs had the lowest death risk of all (HR = 0.44) ✅ Plasma proteomics tracks aging better than existing clinical clocks (like PhenoAge) 💡 The promise for longevity: If we can measure, protect, and intervene on the aging of specific organs — especially the brain and immune system — we might delay chronic disease and extend healthspan. Massive kudos to the phenomenal team across Stanford, the UK Biobank Pharma Proteomics Project, and the Wu Tsai Neurosciences Institute for making this possible. A milestone in translational aging science! BRAIN AND IMMUNE SYSTEM YOUTH PREDICT LONGEVITY #longevity #aging #biomarkers #proteomics #brainhealth #immunology

🚀 I just got back from A4M—the biggest anti-aging conference in the U.S.—here are my top 10 takeaways: 1. “Fringe” therapies are going mainstream. Ever heard of Therapeutic Plasma Exchange? It sounds wild—they drain your blood and replace plasma to clear out heavy metals, mold, and infections. But here’s the kicker: early data shows it can improve 30+ longevity biomarkers. It’s no crazier than cold plunges or red light therapy once sounded. Once these treatments get cheaper, they’ll be everywhere. Dr. Darshan Shah and Dobri Kiprov are leading the way. 2. Peptides are unstoppable. Despite regulatory headwinds, the demand for peptides hasn’t slowed. Custom formulations are thriving, doctors are obsessed, and GLP-1 drugs (like Ozempic) have only fanned the flames. This train isn’t stopping. 3. Women’s health is finally getting its moment and making up for lost time. From pregnancy to postpartum to menopause, care for women is getting nuanced and comprehensive. Doctors are focusing on the emotional and medical needs of every phase. This isn’t just healthcare—it’s care. Erika Schwartz, MD mastered this. 4. The rise of compounding pharmacies. Patients want customized treatments—tailored formulations, better delivery methods, and lower costs. Compounding pharmacies are taking big risks to meet that demand, and it’s pushing the entire industry forward. 5. Peter Attia dropped the mic (again). No one understands longevity like Peter Attia. His best line? “You cannot overestimate the importance of exercise. Contracting a muscle literally lowers blood sugar by bringing glucose receptors to the surface.” Simple. Actionable. Science-backed. 6. Love, Awe, and Mindset might be the real magic. We’re obsessed with the newest treatments, but the best doctors know this: ✨ Love ✨ Awe ✨ Mindset These emotions lower stress hormones, make us feel safe, and are huge predictors of longevity. Don't skip the human side of health. 7. AI + quantum computing will make doctors superhuman. In the next few years, healthcare information will increase by 3x.  Forward-looking doctors aren’t afraid of AI—they see it as a tool. Doctors aren’t being replaced—they’re becoming healers powered by machines that will unlock the kind of insights we can’t yet imagine. 8. Longevity is personal. There won’t be one magic protocol. The winners will create frameworks that let doctors deliver N=1 care—custom treatments for every individual. Longevity is a journey, not a prescription. 9. Longevity leaders are stepping up. Physicians and founders like David Luu, MD are building global, research-based communities like Longevity Docs to push boundaries and innovate. The people driving this movement are bold, brilliant, and collaborative. 10. Diagnostics are changing the game. Precision testing is the bedrock of modern longevity care. Doctors are demanding more specific insights to fine-tune treatment plans. TruDiagnostic and Ryan Smith are leading the charge here.

Here is the post my friends in pharma interested in aging research may like. Imagine that every time you were doing IND-enabling studies, you could also run a lifespan study in mouse... Every pharma program hits the 12-month IND-enabling window. Why not use that same year to run a parallel mouse lifespan study—and almost nobody is doing it yet. Why pair lifespan with IND tox? • You’re already paying for PCC/DC safety—start dosing aged UM-HET3 mice on day 1 and read out survival before FIH. • Catch late-onset toxicities early, adjust dose or schedule, and avoid a nine-figure clinical blow-up. • Best case: your chronic-use drug quietly doubles as a geroprotector—instant differentiation for investors and regulators. Our plug-and-play protocol • 250 UM-HET3 per group (176 ♂ / 72 ♀) → 10 % lifespan shift at 80 % power. • Preventive (4 mo) or late-life (16-20 mo) start; compound in chow to minimize stress. • Core readouts: survival curves, body-weight, core temp—simple, low-cost, predictive. • Add-ons: automated video phenotyping, quarterly multi-omics, histopathology for MoA. • All fits comfortably inside the standard IND timeline and budget. The concept brought to you by: Qian Wang, Yujie Liu, Wenbin Hou, Yuelei Shen Dominika Wilczok, Kristen Fortney, Alex Aliper, Man Zhang, Feng Ren, Richard A. Miller, and yours truly. If you’re serious about aging science—or just de-risking development—let’s talk about integrating true long-term safety into your next IND. #DrugDiscovery #Longevity #PreclinicalResearch #IND #AgingScience Read the paper: https://lnkd.in/ewnJdzkz

In this episode (# 357) of The Drive, I sit down with Brian Kennedy, Ph.D., a renowned biologist, leader in aging research, and director of the Center for Healthy Longevity at the National University of Singapore. Brian shares insights from ongoing human aging studies, including clinical trials of rapamycin and how dosing strategies, timing, and exercise may influence outcomes. He presents two key models of aging—one as a linear accumulation of biological decline and the other as an exponential rise in mortality risk—and explains why traditional models of aging fall short. He also explains why most current aging biomarkers lack clinical utility and describes how his team is working to develop a more actionable biological clock. Additional topics include the potential of compounds like alpha-ketoglutarate, urolithin A, and NAD boosters, along with how lifestyle interventions—such as VO2 max training, strength building, and the use of GLP-1 and SGLT2 drugs—may contribute to longer, healthier lives. We also discuss: -Speculating on the future of longevity: slowing biological aging through noise reduction and reprogramming -Comparing the big 4 chronic diseases: which are the most inevitable and modifiable? -Why combining too many longevity interventions may backfire -Other interventions that may promote longevity: spermidine, 17𝛼-estradiol, HRT, and more -More Click to watch or listen to the full episode on my website. https://bit.ly/45bnvxR

𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐨𝐟 𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰™: Hormone Recalibration as the Operating System for Longevity Hormones are not episodic events. They are the upstream architecture of biological aging. From skin quality to bone density, immune tone to sleep regulation, hormone signaling governs the rhythm, resilience, and repair of every tissue. Yet conventional medicine treats hormones as static values—measured too late, replaced too broadly, and monitored too rarely. The result is a model based on crisis response, not recalibration. The next evolution in longevity care will shift from replacement to re-synchronization—training the body to regain hormonal precision in real time. 𝗧𝗵𝗲 𝗡𝗲𝘄 𝗙𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸: 𝗜𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝘁, 𝗖𝗹𝗼𝘀𝗲𝗱-𝗟𝗼𝗼𝗽 𝗛𝗼𝗿𝗺𝗼𝗻𝗲 𝗔𝗿𝗰𝗵𝗶𝘁𝗲𝗰𝘁𝘂𝗿𝗲 ➡️Hormone Operating Systems AI-trained systems built on individual hormone rhythms, not population averages. These platforms integrate endocrine biomarkers with contextual data: circadian disruption, follicular shifts, sleep architecture, and glymphatic clearance. ➡️Microfluidic Biosensors Transdermal hormone metabolite readers that detect fluctuations in cortisol, estradiol, melatonin, IGF-1, and TSH—feeding into adaptive feedback protocols. ➡️Real-Time Modulation Interfaces Light, sound, and neuroelectrical inputs used to recalibrate key axes: – Pineal-melatonin signaling through programmable light therapy – Cortisol awakening response through dawn-phase entrainment – HPA tone adjustment through neurostimulation of parasympathetic nodes – Thyroid support via anterior neck photobiomodulation ➡️Precision Dispensers At-home robotic platforms that deliver microdose, gland-specific therapeutics: – Intranasal oxytocin adjusted by social input metrics – Transdermal T3 linked to early thyroid drift indicators – Vaginal estriol nanodose gels triggered by mucosal thermodynamics – IGF-1 synchronized to post-exertional tissue demand • Predictive Tissue Forecasting AI models simulating how estrogen receptor density, cortisol phase lag, or androgen balance will influence dermal ECM, scalp follicle cycling, or metabolic resilience. 💊Example Therapies: – Estradiol peptides delivered to collagen-dense zones during high receptor expression windows – Melatonin optimization via GABAergic topicals, HRV, and ambient light detection – T3–lipid interface repair through wearable thyroid sensors and mitochondrial light therapy – Androgen recalibration using biofeedback from scalp sebum mapping and stress markers This is not hormone therapy, it’s hormonal systems engineering—rooted in endocrine logic, built on real-time data, and applied through closed-loop, adaptive care. Longevity will not be governed by lifespan alone, but by the quality of endocrine regulation driving each regenerative signal. #TreatmentsOfTomorrow #Longevity #Precision #Endocrinology #Neuroendocrine #AIinLongevity #SkinAnarchy #FutureOfWellness 🔁 and follow Skin Anarchy The Podcast for more

One of the most promising areas of advancement is in the field of longevity. 1. AI in Longevity Research AI technologies can be used to analyze vast amounts of health data, identify biomarkers as they relate to aging, and understand the complex mechanisms behind longevity. By integrating AI with genomics and biotechnology, researchers may be able to predict health trajectories and personalize medical treatments, reducing morbidity. 2. Personalized Medicine One of the most impactful applications of AI in longevity is in the development of personalized medicine. AI algorithms can process individual genetic information, lifestyle data from wearables and other continuous tools, as well environmental factors to tailor preventive and therapeutic solutions specifically designed for each person's unique biological makeup. 3. Global Collaboration AI is not only a tool but a bridge connecting researchers, clinicians, and innovators worldwide. Through global data sharing and collaboration facilitated by AI, the longevity field is experiencing unprecedented growth and innovation. It allows stakeholders to connect and share ideas and insights. As we look to the future, the potential of AI to transform our understanding and approach to aging is boundless. Let's continue to support and invest in these technologies that promise not only to extend life but to enhance the quality of our years. Yes, we have to ask tough questions about their development and use. That will allow us to shape the technologies to our needs. #Longevity #ArtificialIntelligence #HealthTech #Innovation #PersonalizedMedicine #aging